Disease-modifying drugs in relapsing-remitting multiple sclerosis: evidence-based treatment algorithm for Latin America

被引：0
|
作者：
Finkelsztejn, A.
Gabbai, A. A.
Fragoso, Y. D.
Carra, A.
Macias-Islas, M. A.
Arcega Revilla, R.
Garcia Bonitto, J.
Oehninger Gatti, C. L.
Orozco Escobar, G.
Tarulla, A.
Vergara, F.
Vizcarra, D.
机构：
[1] Hosp Clin, Porto Alegre, RS, Brazil
[2] Univ Fed Sao Paulo, Sao Paulo, Brazil
[3] Univ Metropolitana Santos, Santos, Brazil
[4] Hosp Britan, Buenos Aires, DF, Argentina
[5] Univ Guadalajara, CUCS, Guadalajara 44430, Jalisco, Mexico
[6] Inst Mexicano Seguro Social, Hosp Especialidades, Puebla, Mexico
[7] Colombian Multiple Sclerosis Res & Treatment Comm, Bogota, Colombia
[8] Hosp Clin Montevideo, Montevideo, Uruguay
[9] Hosp Patrocinio Penuela Ruiz, San Cristobal, Venezuela
[10] Inst Invest Med Alfredo Lanari, Buenos Aires, DF, Argentina
[11] Univ Los Andes, Santiago, Chile
[12] Univ Peruana Cayetano Heredia, Lima, Peru
来源：
MULTIPLE SCLEROSIS JOURNAL | 2011年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P997
引用
收藏
页码：S452 / S453
页数：2
相关论文
共 50 条
  • [21] Disease reactivation after cessation of disease-modifying therapy in relapsing-remitting multiple sclerosis
    Roos, I.
    Malpas, C. B.
    Leray, E.
    Buzzard, K.
    Skibina, O.
    Lechner-Scott, J.
    McCombe, P.
    Slee, M.
    Butler, E.
    Macdonell, R.
    van der Walt, A.
    Hodgkinson, S.
    Barnett, M.
    Vucic, S.
    Vukusic, S.
    Butzkueven, H.
    Kalincik, T.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 : 6 - 7
  • [22] Comparing the Cost-Effectiveness of Disease-Modifying Drugs for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis
    Goldberg, Lawrence D.
    Edwards, Natalie C.
    Fincher, Contessa
    Doan, Quan V.
    Al-Sabbagh, Ahmad
    Meletiche, Dennis M.
    JOURNAL OF MANAGED CARE PHARMACY, 2009, 15 (07): : 543 - 555
  • [23] When to Initiate Disease-Modifying Drugs for Relapsing Remitting Multiple Sclerosis in Adults?
    Alkhawajah, Mona
    Oger, Joel
    MULTIPLE SCLEROSIS INTERNATIONAL, 2011, 2011
  • [24] The Effects of Disease-Modifying Therapies on Oxidative Stress in Patients With Relapsing-Remitting Multiple Sclerosis
    Topic, Aleksandra
    Vasic, Marija
    Markovic, Bojan
    Milinkovic, Neda
    Dincic, Evica
    CLINICAL NEUROPHARMACOLOGY, 2022, 45 (06) : 157 - 161
  • [25] Olfactory Dysfunction in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Disease-Modifying Therapies
    Wnuk, Marcin
    Drabik, Leszek
    Marona, Monika
    Szaleniec, Joanna
    Bryll, Amira
    Karcz, Paulina
    Kolasinska, Justyna
    Kolasinska, Monika
    Ziekiewicz, Maciej
    Skladzien, Jacek
    Popiela, Tadeusz
    Slowik, Agnieszka
    ENT-EAR NOSE & THROAT JOURNAL, 2022, 101 (10) : 640 - 644
  • [26] Injectable Disease-Modifying Therapy for Relapsing-Remitting Multiple Sclerosis: A Review of Adherence Data
    Caon, Christina
    Saunders, Carol
    Smrtka, Jennifer
    Baxter, Nancy
    Shoemaker, Jennifer
    JOURNAL OF NEUROSCIENCE NURSING, 2010, 42 (05) : S5 - S9
  • [27] Use of Disease-Modifying Therapies in Pediatric Relapsing-Remitting Multiple Sclerosis in the United Kingdom
    Abdel-mannan, Omar A.
    Manchoon, Celeste
    Rossor, Thomas
    Southin, Justine-Clair
    Tur, Carmen
    Brownlee, Wallace
    Byrne, Susan
    Chitre, Manali
    Coles, Alasdair
    Forsyth, Rob
    Kneen, Rachel
    Mankad, Kshitij
    Ram, Dipak
    West, Siobhan
    Wright, Sukhvir
    Wassmer, Evangeline
    Lim, Ming
    Ciccarelli, Olga
    Hemingway, Cheryl
    Hacohen, Yael
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2021, 8 (04):
  • [28] Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis A meta-analysis
    Landmeyer, Nils C.
    Buerkner, Paul-Christian
    Wiendl, Heinz
    Ruck, Tobias
    Hartung, Hans-Peter
    Holling, Heinz
    Meuth, Sven G.
    Johnen, Andreas
    NEUROLOGY, 2020, 94 (22) : E2373 - E2383
  • [29] Patient perspective on decisions to switch disease-modifying treatments in relapsing-remitting multiple sclerosis
    Manzano, A.
    Eskyte, I
    Ford, H. L.
    Pavitt, S. H.
    Potrata, B.
    Schmierer, K.
    Chataway, J.
    Webb, E. J. D.
    Meads, D.
    Pepper, G.
    Bekker, H. L.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 46
  • [30] Disease-Modifying Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis: A Comparison of Their Efficacy for Reducing Relapse Rate
    Lingohr-Smith, M.
    Deitelzweig, C.
    Lin, G.
    Lin, J.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (1_SUPPL) : 34 - 35
12345